Drug General Information (ID: DDI50TJMK7)
Drug Name			Atropine		Drug Info		Potassium chloride		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiarrhythmic Agents				Dietary Supplement
Structure

Mechanism of Atropine-Potassium chloride Interaction (Severity Level: Major)
Altered gastrointestinal dynamics Click to Show/Hide Mechanism Graph
Drug Name		Atropine				Potassium chloride
Mechanism		Delayed gastric emptying				Absorption affected by delayed gastric emptying
Key Mechanism Factor 1
		Factor Name		Gastrointestinal Motility
		Factor Description		Gastrointestinal motility is an important factor in determining the absorption of orally administered drugs, and it controls the residence time of the drug in the digestive tract.
Mechanism Description		Altered absorption of Potassium chloride due to GI dynamics variation caused by Atropine

Recommended Action
Management		The use of oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium chloride should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.

References
1	Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
2	Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746. [PMID: 1139204]
3	Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11. [PMID: 7424872]
4	Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7. [PMID: 2856988]
5	Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8. [PMID: 4013604]
6	Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5. [PMID: 7123349]
7	McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5. [PMID: 6734038]
8	McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61. [PMID: 6127542]
9	Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
10	Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2. [PMID: 830293]
11	Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546. [PMID: 5850476]